Stay updated with breaking news from ஹம்ஸா சூரியா. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
European Commission Approves JEMPERLI (dostarlimab), the First Anti-PD-1 Therapy Approved for Recurrent or Advanced dMMR/MSI-H Endometrial Cancer in Europe globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Provided by Dow Jones By Adriano Marchese AnaptysBio Inc. said Thursday that the U.S. Food and Drug Administration approved GlaxoSmithKline PLC s biologics license application for JEMPERLI, a treatment for endometrial cancer. The clinical-stage biotechnology company said JEMPERLI, also known as dostarlimab-gxly, was generated by AnaptysBio and developed by TESARO Inc. now a part of GSK under a collaboration agreement. AnaptysBio received a $20 million milestone payment as part of the approval. A Biologics License Application for JEMPERLI a treatment for patients with mismatch repair deficient recurrent or advanced endometrial cancer is needed to obtain permission for distribution across U.S. states. This event provides important validation for our proprietary SHM antibody discovery platform and provides significant potential future milestone and royalty revenue to support AnaptysBio s growth, President and Chief Exe ....
AnaptysBio Announces Appointment of Oleg Nodelman to Board of Directors SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced the appointment of Oleg Nodelman to the company’s Board of Directors. “Oleg is an experienced biotechnology company builder with deep insight in the development and financing of novel therapies,” said Hamza Suria, president and chief executive officer of AnaptysBio. “We welcome Oleg to our Board of Directors and look forward to his contributions to AnaptysBio’s capital-efficient antibody discovery and development business model.” ....
Author Bio Eric has been writing about stocks and finance since the mid-1990s, when he lived in Prague, Czech Republic. Over the course of a varied career, he has also been a radio newscaster, an investment banker, and a bass player in a selection of rock and roll bands. A native New Yorker, he currently lives in Los Angeles. What happened Tech investors who are glum about the recent performances of their holdings have nothing on AnaptysBio (NASDAQ:ANAB). The clinical-stage biotech s shares fell off a cliff on Monday, dropping nearly 34% on very discouraging news about a clinical study. ....